Drugs / bone marrow mononuclear cell
bone marrow mononuclear cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT00813267 | Dec 2009 → Aug 2011 | osteonecrosis | Jianming Tan | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bone marrow mononuclear cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00813267 ↗ |
| Known as | BMMNC | “Bone marrow mononuclear cells (BMMNCs) have revascularization properties and complimentary effects to MSCs.” NCT00813267 ↗ |
| Known as | BMMNCs | “Bone marrow mononuclear cells (BMMNCs) have revascularization properties and complimentary effects to MSCs.” NCT00813267 ↗ |
| Modality | Cell therapy | “Patients in this study will receive infusion of expanded autologous MSC and BMMNCs.” NCT00813267 ↗ |
| Route | Other | “The investigators will infuse expanded autologous MSCs and BMMNCs into patients with osteonecrosis of the femoral head.” NCT00813267 ↗ |